Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

An open-label study to evaluate the safety and the ability of Imiquimod 5% cream, applied topically, to clear superficial basal cell carcinoma and to keep it clear for 5 years of follow-up.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Graceway Pharmaceuticals, LLC
• Treatments: Imiquimod

Criteria

Inclusion Criteria:

• Have at least 1 previously untreated superficial basal cell carcinoma tumor

• Minimum tumor size 0.5 cm2 and maximum diameter of 2.0 cm

Exclusion Criteria:

• Evidence of clinically significant, unstable medical conditions

• Cannot have recent use of topical steroids or retinoids in the treatment area.